|
|
 |
|
Viewing report
|
|
|
|
The Pharmaceutical Market: India
Espicom Business Intelligence Ltd, Oct 2011, Pages: 124
THE PHARMACEUTICAL MARKET: INDIA - REVIEW
The Indian pharmaceutical market is highly competitive and remains dominated by low priced, domestically-produced generics. Despite having the second largest population in the world and a growing middle class with high healthcare expectations, India accounts for less than 2% of the world pharmaceutical market in value terms. In one of the world's better performing economies, spending on pharmaceuticals accounts for less than 1% of GDP and average per capita spending remains one of the lowest levels in the region.
India’s biopharmaceutical sector is currently experiencing double digit growth and this is expected to continue, driven by the vaccines market. Growth drivers include education and increased awareness of disease prevention, increases in disposable income and government participation in immunisation programmes. Continued growth is also expected in the diagnostic and therapeutic segments, including cancer and diabetes. India is already known as the diabetic capital of the world and the number of diabetes patients in India is expected to grow to 70 million by 2025. Cancer therapies are also lucrative for many Indian companies due to high unmet need, increased awareness and the comparative affordability of domestically produced drugs.
The Indian pharmaceutical industry is responsible for around 8% of world pharmaceutical production. Over the last few years, a number of Indian companies have been targeted for foreign acquisition. Concerns have been raised that this trend could adversely affect generic drug prices in India. The Ministry of Health wants safeguards built into the Foreign Direct Investment process amid fears that continued foreign acquisitions will adversely affect the domestic industry and push prices up, thereby potentially undermining the government’s efforts to make generic drugs affordable. This could lead to essential medicines becoming more expensive and adversely affecting public health programmes.
During 2011, in May Par Pharmaceutical Companies entered into a definitive agreement to acquire privately-held Edict Pharmaceuticals, a Chennai-based developer and manufacturer of solid oral dosage generics. In April, Hikma Pharmaceuticals announced that it had agreed to acquire a minority interest in Unimark Remedies, is a privately-held Indian manufacturer of active pharmaceutical ingredients and API intermediaries. Over the last few years a number of Indian businesses have been partially or fully acquired by international companies, notably Dabur Pharma (Fresenius Kabi), Matrix Laboratories (Mylan), Ranbaxy (Daiichi Sankyo), Orchid’s generic formulations (Hospira) and Piramal’s domestic formulations business (Abbott).
ENHANCED STRATEGIC INTELLIGENCE
These highly regarded world pharmaceutical market reports have been redesigned to provide enhanced strategic intelligence in a user-friendly format. Each report provides in-depth information, setting the pharmaceutical market in context. The reports provide:
- Five-year projections for economic, demographic, health expenditure, health workforce and pharmaceutical market indicators.
- Specialised intelligence on OTCs, generics, biologics and biosimilars.
- Exclusive economic and demographic data from the Economist Intelligence Unit (EIU) for each market in the series.
- A separate statistical health file, comprising health expenditure, health infrastructure, health services and health personnel.
- The reports are updated quarterly, providing you with the latest information for a full year. In addition, the service will keep you up to date with market and industry news on a regular basis.
HEALTHCARE STATISTICS
A comprehensive tabula review, comprising demographics, epidemiology, health expenditure, hospital and primary care infrastructure & services and healthcare personnel, is additionally included.
Customers who bought this item also bought
The Pharmaceutical Market: Canada
The Pharmaceutical Market: Malaysia
The Pharmaceutical Market: Pakistan
The Pharmaceutical Market: China
The Pharmaceutical Market: Japan
The Pharmaceutical Market: Saudi Arabia
The Pharmaceutical Market: Mexico
The Pharmaceutical Market: Argentina
The Pharmaceutical Market: Israel
The Pharmaceutical Market: Switzerland
|
|
|
|
